The results showed similar immune efficacy in eliciting a specific anti-tumor response, highlighting however that PeptiCRAd could induce more activated and cytolytic immunophenotypes in the CD8+ T cells population compared to AdEpitopes. The gene discussed is CD8A; the disease is neoplasm.